






Supplementary table 1. Recorded variables for each patient. (Not all trial visits are represented).

PATIENT 1. Male, 36 yo	Baseline Visit	1 st visit	2 nd visit	3 rd visit	Last Clinical Trial Visit
UCVA					
Right eye	0,6/0,8	0,8+1/0,8+1	0,8 +2 /0,8 +2	0,8 +2 /0,8 +2	0,7/0,7
Left eye	1	1,25	1.25	1.25	1
Slit lamp examination	Normal	Normal	Normal	Normal	Normal
IOP (mmHg)					
Right eye	15	12	13	12	12
Left eye	15	10	14	14	10
Funduscopy					
Right eye	1 Peripheral hemangioblastoma in superior temporal retinal area, treated with laser photocoagulation showing great exudation in FA.	1 Peripheral hemangioblastoma still showing great exudation.	Apparently, increased exudation.	Exudation in resolution.	No exudation at the end of the trial.
Left eye	1 pre-existent peripheral hemangioblastoma treated with laser photocoagulation.	No changes	No changes	No changes	No changes
Retinography/FA					
Right eye					
					Intermediate image, after 10 months of treatment:

				
Left eye	  	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
OCT <i>Macular</i>		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>

Optic nerve	<table border="1"> <thead> <tr> <th></th> <th>OD</th> <th>OS</th> </tr> </thead> <tbody> <tr> <td>Grosor RNFL promedio</td> <td>104 µm</td> <td>86 µm</td> </tr> <tr> <td>Simetria RNFL</td> <td colspan="2">85%</td></tr> </tbody> </table>		OD	OS	Grosor RNFL promedio	104 µm	86 µm	Simetria RNFL	85%				
	OD	OS											
Grosor RNFL promedio	104 µm	86 µm											
Simetria RNFL	85%												
Propranolol dosage	None	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)									
Comments	<p>This patient had had multiple tumours which required multiple photocoagulations. After 11 months of treatment, he had to suspend it for three months due to a neurosurgery for CNS hemangioblastoma. His regular ophthalmologist wrote in his clinical history "no new lesions/no active lesions" during the following year. He had also the most significant reduction in VEGF levels along the study. At present, he continues taking propranolol off-label.</p>												



LEGEND




UCVA - Uncorrected visual acuity

IOP – Intraocular pressure




FA – Fluorescein angiography











OCT - Optical coherence tomography

PATIENT 2. Female, 33 yo	Baseline Visit	1st visit	2nd visit	3rd visit	October 2016 – continued taking propranolol – off-label
UCVA Right eye 1 0,6	1 0,6	1 0,8+2	1 0,8	1 0,8	1 0,6
Slit lamp examination	Normal	Normal	Normal	Normal	Normal
IOP (mmHg) Right eye 16	16	12	14	12	10
Left eye	16	10	14	10	10
Funduscopy Right eye	<i>2 pre-existent hemangioblastomas located one superior and other inferior treated with laser photocoagulation, no exudation</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
Left eye	<i>1 juxtapapillary hemangioblastoma, late hyperfluorescence. Epiretinal membrane</i>	<i>Less exudation</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
Retinography /FA Right eye		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
Left eye	 				

				
OCT <i>Macular</i>	 	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
<i>Optic nerve</i>		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
Propranolol dosage	<i>None</i>	<i>120 mg/day (40 mg/ 8 h)</i>	<i>120 mg/day (40 mg/ 8 h)</i>	<i>120 mg/day (40 mg/ 8 h)</i>
Comments	<i>At present, she continues taking propranolol off-label.</i>			




LEGEND
UCVA - Uncorrected visual acuity
IOP - Intraocular pressure
FA - Fluorescein angiography
OCT - Optical coherence tomography










PATIENT 3. Female, 50 yo	Baseline Visit	1st visit	2nd visit	3rd visit	Last Clinical Trial Visit
UCVA Right eye Left eye	1,6 0,1/0,12	1,6 0,12	1,2 0,1	1 0,1/0,2	1 0,1/0,2
Slit lamp examination	Normal	Normal	Normal	Normal	Normal
IOP (mmHg) Right eye Left eye	16 18	16 16	18 18	12 12	14 18
Funduscopy Right eye Left eye	Normal <i>Juxtapapillary hemangioblastoma showing great exudation and macular edema.</i>	Normal <i>No changes</i>	Normal <i>Less exudation</i>	Normal <i>Retinal exudation has almost disappeared</i>	Normal <i>Exudation still persists</i>
Retinography/FA Right eye		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
Left eye	 	 			


OCT Macular		<i>Left's eye macular edema decreased 190 µm.</i>	<i>In this visit, left's eye macular edema remained stable. It only decreased 9 µm.</i>	<i>In last visit, macular edema augmented 45 µm.</i>
				
				
				
				
Optic nerve				
				
				
				
				
Propranolol dosage	<i>None</i>	<i>120 mg/day (40 mg/ 8 h)</i>	<i>120 mg/day (40 mg/ 8 h)</i>	<i>120 mg/day (40 mg/ 8 h)</i>
Comments	<i>This patient and patient 4 are mother and son. They had the same regular ophthalmologist, who had written in their clinical histories that both of them had a severe retinal affection with proliferation, and the tractional component would limit the results.</i>			









LEGEND




UCVA - Uncorrected visual acuity
IOP - Intraocular pressure
FA - Fluorescein angiography
OCT - Optical coherence tomography

PATIENT 4. Male, 20 yo	Baseline Visit	1st visit	2nd visit	3rd visit	Last Clinical Trial Visit
UCVA					
Right eye	1,6	1,6	1,6	1,6	1,6
Left eye	0,12	0,12	0,12	0,12	0,1
Slit lamp examination	Normal	Normal	Normal	Normal	Normal
IOP (mmHg)					
Right eye	16	16	15	16	14
Left eye	16	16	17	16	13
Funduscopy					
Right eye	Normal	Normal	Normal	Normal	Normal
Left eye	<i>Juxtapapillary hemangioblastoma and cystoid macular edema. Early hyperfluorescence.</i>	<i>Although lesions persist, exudation has improved.</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
Retinography/FA					
Right eye		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
Left eye	    				
					



OCT Macular																																																																
	<table border="1"><thead><tr><th>ILM - RPE</th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor del subcampo central (μm)</td><td>268</td><td>939</td></tr><tr><td>Cubo de volumen (mm³)</td><td>10,4</td><td>19,2</td></tr><tr><td>Cubo grosor prom. (μm)</td><td>288</td><td>535</td></tr></tbody></table>	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	268	939	Cubo de volumen (mm ³)	10,4	19,2	Cubo grosor prom. (μm)	288	535	<table border="1"><thead><tr><th>ILM - RPE</th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor del subcampo central (μm)</td><td>264</td><td>774</td></tr><tr><td>Cubo de volumen (mm³)</td><td>10,3</td><td>18,7</td></tr><tr><td>Cubo grosor prom. (μm)</td><td>287</td><td>518</td></tr></tbody></table>	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	264	774	Cubo de volumen (mm ³)	10,3	18,7	Cubo grosor prom. (μm)	287	518	<table border="1"><thead><tr><th>ILM - RPE</th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor del subcampo central (μm)</td><td>260</td><td>697</td></tr><tr><td>Cubo de volumen (mm³)</td><td>10,4</td><td>22,1</td></tr><tr><td>Cubo grosor prom. (μm)</td><td>288</td><td>614</td></tr></tbody></table>	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	260	697	Cubo de volumen (mm ³)	10,4	22,1	Cubo grosor prom. (μm)	288	614	<table border="1"><thead><tr><th>ILM - RPE</th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor del subcampo central (μm)</td><td>262</td><td>1017</td></tr><tr><td>Cubo de volumen (mm³)</td><td>10,3</td><td>18,7</td></tr><tr><td>Cubo grosor prom. (μm)</td><td>285</td><td>520</td></tr></tbody></table>	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	262	1017	Cubo de volumen (mm ³)	10,3	18,7	Cubo grosor prom. (μm)	285	520	<table border="1"><thead><tr><th>ILM - RPE</th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor del subcampo central (μm)</td><td>261</td><td>1101</td></tr><tr><td>Cubo de volumen (mm³)</td><td>10,4</td><td>19,6</td></tr><tr><td>Cubo grosor prom. (μm)</td><td>288</td><td>546</td></tr></tbody></table>	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	261	1101	Cubo de volumen (mm ³)	10,4	19,6	Cubo grosor prom. (μm)	288
ILM - RPE	OD	OS																																																														
Grosor del subcampo central (μm)	268	939																																																														
Cubo de volumen (mm ³)	10,4	19,2																																																														
Cubo grosor prom. (μm)	288	535																																																														
ILM - RPE	OD	OS																																																														
Grosor del subcampo central (μm)	264	774																																																														
Cubo de volumen (mm ³)	10,3	18,7																																																														
Cubo grosor prom. (μm)	287	518																																																														
ILM - RPE	OD	OS																																																														
Grosor del subcampo central (μm)	260	697																																																														
Cubo de volumen (mm ³)	10,4	22,1																																																														
Cubo grosor prom. (μm)	288	614																																																														
ILM - RPE	OD	OS																																																														
Grosor del subcampo central (μm)	262	1017																																																														
Cubo de volumen (mm ³)	10,3	18,7																																																														
Cubo grosor prom. (μm)	285	520																																																														
ILM - RPE	OD	OS																																																														
Grosor del subcampo central (μm)	261	1101																																																														
Cubo de volumen (mm ³)	10,4	19,6																																																														
Cubo grosor prom. (μm)	288	546																																																														
<p>Great cystic macular edema, 939 μm.</p>	<p>Macular edema decreased 165 μm.</p>	<p>It continued decreasing to 77 μm.</p>	<p>Macular edema increased, reaching 1017 μm, and so happened with optic nerve measures.</p>	<p>No improvement is seen in the last visit.</p>																																																												
																																																																
<table border="1"><thead><tr><th></th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor RNFL promedio</td><td>97 μm</td><td>159 μm</td></tr><tr><td>Simetría RNFL</td><td>41%</td><td></td></tr></tbody></table>		OD	OS	Grosor RNFL promedio	97 μm	159 μm	Simetría RNFL	41%		<table border="1"><thead><tr><th></th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor RNFL promedio</td><td>96 μm</td><td>106 μm</td></tr><tr><td>Simetría RNFL</td><td>37%</td><td></td></tr></tbody></table>		OD	OS	Grosor RNFL promedio	96 μm	106 μm	Simetría RNFL	37%		<table border="1"><thead><tr><th></th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor RNFL promedio</td><td>98 μm</td><td>125 μm</td></tr><tr><td>Simetría RNFL</td><td>11%</td><td></td></tr></tbody></table>		OD	OS	Grosor RNFL promedio	98 μm	125 μm	Simetría RNFL	11%		<table border="1"><thead><tr><th></th><th>OD</th><th>OS</th></tr></thead><tbody><tr><td>Grosor RNFL promedio</td><td>X</td><td>113 μm</td></tr><tr><td>Simetría RNFL</td><td></td><td></td></tr></tbody></table>		OD	OS	Grosor RNFL promedio	X	113 μm	Simetría RNFL																											
	OD	OS																																																														
Grosor RNFL promedio	97 μm	159 μm																																																														
Simetría RNFL	41%																																																															
	OD	OS																																																														
Grosor RNFL promedio	96 μm	106 μm																																																														
Simetría RNFL	37%																																																															
	OD	OS																																																														
Grosor RNFL promedio	98 μm	125 μm																																																														
Simetría RNFL	11%																																																															
	OD	OS																																																														
Grosor RNFL promedio	X	113 μm																																																														
Simetría RNFL																																																																
Propranolol dosage	None	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)																																																											
Comments	This patient and patient 3 are son and mother. They had the same regular ophthalmologist, who had written in their clinical histories that both of them had a severe retinal affection with proliferation, and the tractional component would limit the results.																																																															










PATIENT 5. Male, 15 yo	Baseline Visit	1st visit	2nd visit	Last Clinical Trial Visit	February 2017 – having discontinued propranolol
UCVA Right eye Left eye	1 1,2	1,25 1,25	1,25 1,25	1 1,25	1 1
Slit lamp examination	Normal	Normal	Normal	Normal	Normal
IOP (mmHg) Right eye Left eye	18 18	15 13	15 13	11 9	14 13
Funduscopy Right eye Left eye	1 peripheral hemangioblastoma located inferior temporal, treated with laser photocoagulation, showing dilated vessels. Normal	No changes Normal	The tumour seemed a little bit more retracted, although it had the same size. Normal	No changes Normal	The tumour appeared larger and congested. Normal
Retinography/FA Right eye	          <p>Early hyperfluorescence</p>				

Left eye		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>												
OCT Macular	<table border="1"> <thead> <tr> <th>ILM - RPE</th> <th>OD</th> <th>OS</th> </tr> </thead> <tbody> <tr> <td>Grosor del subcampo central (μm)</td> <td>301</td> <td>278</td> </tr> <tr> <td>Cubo de volumen (mm³)</td> <td>10,8</td> <td>10,3</td> </tr> <tr> <td>Cubo grosor prom. (μm)</td> <td>301</td> <td>286</td> </tr> </tbody> </table> 	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	301	278	Cubo de volumen (mm ³)	10,8	10,3	Cubo grosor prom. (μm)	301	286	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>
ILM - RPE	OD	OS															
Grosor del subcampo central (μm)	301	278															
Cubo de volumen (mm ³)	10,8	10,3															
Cubo grosor prom. (μm)	301	286															
Optic nerve	 <table border="1"> <thead> <tr> <th></th> <th>OD</th> <th>OS</th> </tr> </thead> <tbody> <tr> <td>Grosor RNFL promedio</td> <td>115 μm</td> <td>96 μm</td> </tr> <tr> <td>Simetría RNFL</td> <td>86%</td> <td></td> </tr> </tbody> </table>		OD	OS	Grosor RNFL promedio	115 μm	96 μm	Simetría RNFL	86%		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	<i>No changes</i>			
	OD	OS															
Grosor RNFL promedio	115 μm	96 μm															
Simetría RNFL	86%																
Propranolol dosage	<i>None</i>	<i>120 mg/day (40 mg/ 8 h)</i>															
Comments	<i>After the end of the clinical trial, this patient continued taking propranolol off label for 6 months. Three months after suspension of treatment, he experienced an increase in tumor activity and had to undergo a serial of different treatments to try to control it.</i>																



LEGEND
UCVA - Uncorrected visual acuity
IOP - Intraocular pressure
FA - Fluorescein angiography
OCT - Optical coherence tomography


PATIENT 6. Female, 38 yo	Baseline Visit	1st visit	2nd visit	3rd visit	Withdrawn from the clinical trial due to a scheduled surgery
UCVA Right eye Left eye	1,6 0,1/0,12	1 0,16	1 0,125	1 0,125	-
Slit lamp examination	Normal	Normal	Normal	Normal	-
IOP (mmHg) Right eye Left eye	12 16	16 16	16 17	12 13	-
Funduscopy Right eye Left eye	Normal <i>Juxtapapillary hemangioblastoma surrounded by scar tissue from photodynamic therapy. Exudation.</i>	Normal <i>No changes</i>	Normal <i>No changes</i>	<i>No changes</i> <i>Juxtapapillary hemangioblastoma surrounded by scar tissue from photodynamic therapy. Exudation.</i> <i>Epiretinal membrane and vitreomacular traction syndrome.</i>	-
Retinography/FA Right eye		<i>No changes</i>	<i>No changes</i>	<i>No changes</i>	
Left eye	 		 		Withdrawn





				Withdrawn																																			
OCT Macular	<p>Early hyperfluorescence</p>  <table border="1"> <thead> <tr> <th>ILM - RPE</th> <th>OD</th> <th>OS</th> </tr> </thead> <tbody> <tr> <td>Grosor del subcampo central (μm)</td> <td>260</td> <td>188</td> </tr> <tr> <td>Cubo de volumen (mm³)</td> <td>9.5</td> <td>9.1</td> </tr> <tr> <td>Cubo grosor prom. (μm)</td> <td>264</td> <td>253</td> </tr> </tbody> </table> <p><i>Macular atrophy left eye</i></p>  <table border="1"> <thead> <tr> <th>ILM - RPE</th> <th>OD</th> <th>OS</th> </tr> </thead> <tbody> <tr> <td>Grosor del subcampo central (μm)</td> <td>260</td> <td>224</td> </tr> <tr> <td>Cubo de volumen (mm³)</td> <td>9.5</td> <td>9.8</td> </tr> <tr> <td>Cubo grosor prom. (μm)</td> <td>263</td> <td>272</td> </tr> </tbody> </table>  <table border="1"> <thead> <tr> <th>ILM - RPE</th> <th>OD</th> <th>OS</th> </tr> </thead> <tbody> <tr> <td>Grosor del subcampo central (μm)</td> <td>264</td> <td>668</td> </tr> <tr> <td>Cubo de volumen (mm³)</td> <td>9.6</td> <td>16.4</td> </tr> <tr> <td>Cubo grosor prom. (μm)</td> <td>266</td> <td>455</td> </tr> </tbody> </table>	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	260	188	Cubo de volumen (mm³)	9.5	9.1	Cubo grosor prom. (μm)	264	253	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	260	224	Cubo de volumen (mm³)	9.5	9.8	Cubo grosor prom. (μm)	263	272	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	264	668	Cubo de volumen (mm³)	9.6	16.4	Cubo grosor prom. (μm)	266	455		
ILM - RPE	OD	OS																																					
Grosor del subcampo central (μm)	260	188																																					
Cubo de volumen (mm³)	9.5	9.1																																					
Cubo grosor prom. (μm)	264	253																																					
ILM - RPE	OD	OS																																					
Grosor del subcampo central (μm)	260	224																																					
Cubo de volumen (mm³)	9.5	9.8																																					
Cubo grosor prom. (μm)	263	272																																					
ILM - RPE	OD	OS																																					
Grosor del subcampo central (μm)	264	668																																					
Cubo de volumen (mm³)	9.6	16.4																																					
Cubo grosor prom. (μm)	266	455																																					
Optic nerve	 <p>No changes</p>   <table border="1"> <thead> <tr> <th></th> <th>OD</th> <th>OS</th> </tr> </thead> <tbody> <tr> <td>Grosor RNFL promedio</td> <td>86 μm</td> <td>175 μm</td> </tr> <tr> <td>Simetría RNFL</td> <td>53%</td> <td></td> </tr> </tbody> </table>		OD	OS	Grosor RNFL promedio	86 μm	175 μm	Simetría RNFL	53%																														
	OD	OS																																					
Grosor RNFL promedio	86 μm	175 μm																																					
Simetría RNFL	53%																																						
Propranolol dosage	None	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)																																			
Comments	This patient had a severe retinal disease with important visual impairment. She had to undergo retinal surgery, scheduled before the start of the trial. She was admitted to the trial in an attempt to avoid such surgery, but finally it was inevitable.																																						

LEGEND

UCVA - Uncorrected visual acuity
IOP – Intraocular pressure
FA – Fluorescein angiography
OCT - Optical coherence tomography

PATIENT 7. Male, 22 yo	Baseline Visit	2nd visit	Last Clinical Trial Visit	October 2016 - continued taking propranolol - off-label
UCVA Right eye Left eye	1,25 1,25	1,25 1,25	1,25 1,25	1,25 1,25
Slit lamp examination	Normal	Normal	Normal	Normal
IOP (mmHg) Right eye Left eye	13 14	16 16	12 12	12 13
Funduscopy Right eye Left eye	<i>Large hemangioblastoma located superior with afferent and efferent vessels. Another smaller one located inferior</i> <i>Large hemangioblastoma nasal inferior and another smaller temporal one. inferior</i>	No changes No changes	No changes No changes	No changes No changes
Retinography/FA Right eye	 	 		
	 	 		



		FA: no exudation.														
OCT Macular	 <table border="1"><tr><td>ILM - RPE</td><td>OD</td><td>OS</td></tr><tr><td>Grosor del subcampo central (μm)</td><td>271</td><td>271</td></tr><tr><td>Cubo de volumen (mm³)</td><td>10.7</td><td>10.7</td></tr><tr><td>Cubo grosor prom. (μm)</td><td>296</td><td>298</td></tr></table>	ILM - RPE	OD	OS	Grosor del subcampo central (μm)	271	271	Cubo de volumen (mm³)	10.7	10.7	Cubo grosor prom. (μm)	296	298	No changes	No changes	No changes
ILM - RPE	OD	OS														
Grosor del subcampo central (μm)	271	271														
Cubo de volumen (mm³)	10.7	10.7														
Cubo grosor prom. (μm)	296	298														
Optic nerve	 <table border="1"><tr><td>OD</td><td>OS</td></tr><tr><td>Grosor RNFL promedio</td><td>99 μm</td><td>102 μm</td></tr><tr><td>Simetría RNFL</td><td>83%</td><td></td></tr></table>	OD	OS	Grosor RNFL promedio	99 μm	102 μm	Simetría RNFL	83%		No changes	No changes	No changes				
OD	OS															
Grosor RNFL promedio	99 μm	102 μm														
Simetría RNFL	83%															
Propranolol dosage	None	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)	120 mg/day (40 mg/ 8 h)												
Comments	<i>This patient had rejected standard treatments some time before his inclusion in the clinical trial. At present, he continues taking propranolol off-label.</i>															

LEGEND

UCVA - Uncorrected visual acuity

IOP – Intraocular pressure

FA – Fluorescein angiography

OCT - Optical coherence tomography